Oxford’s COVID-19 Vaccine Shows Promising Results In Early Trials
The experimental vaccine developed by researchers at the University of Oxford has shown a strong immune response in first phases of human trials.
A COVID-19 vaccine that’s currently being tested on humans has shown promising results, according to data published Monday.
In a partnership with global pharmaceutical corporation AstraZeneca, the Oxford-developed vaccine underwent the first two phases of testing. Data from those phases published in the Lancet showed the vaccine produced a strong immune response in participants.
In the first phase of trials, researchers tested a vaccine they’re calling ChAdOx1 nCoV-19 in a study that included 1,077 healthy participants aged 18 to 55.
In the study conducted between April 23 and May 21, researchers found that a majority of participants who received the experimental vaccine produced neutralizing antibodies and T-cells. Triggering the development of T-cells and antibodies have proven to be effective in other vaccinations.
Mature T-cells are a type of white blood cell in the body that can detect foreign antigens and attack them. Researchers have long aimed to develop vaccines that induce T-cells to protect the body against infectious diseases including malaria and HIV.
Researchers behind the vaccine study reported that “there are accumulating data to suggest T-cell responses play an important role in COVID-19 mitigation.” ............